DOD recommends funding for Neumedicines’ Phase I study of recombinant human interleukin-12
Neumedicines’ proposal, ‘Recombinant Interleukin-12, a Broad-Spectrum Biologic for the Treatment of Battle and Traumatic Wound Infections’, was submitted in response to the Fiscal Year 2014 (FY14) Defense Medical
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.